SL-279252 is under clinical development by Shattuck Labs and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SL-279252’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SL-279252 overview

SL-279252 (TAK-252) is under development for the treatment of squamous non-small cell lung cancer, metastatic melanoma, metastatic urothelial cancer, squamous cell carcinoma of the head and neck, squamous cell cervical cancer, gastric or gastro-esophageal junction adenocarcinoma, squamous cell carcinoma of anal canal and skin, renal cell cancer, Hodgkin's lymphoma, diffuse large B cell lymphoma, hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer and oral cavity (mouth) cancer. It comprises two-sided human fusion protein incorporating the extracellular domains of PD-1 and OX40L, adjoined by a central Fc domain. It is administered  intravenously. The drug candidate acts by targeting OX40L receptor and PD L1 and PD L2. It is developed based on agonist redirected checkpoint (ARC) platform. It was also under development for the treatment of lung cancer and colon cancer.

Shattuck Labs overview

Shattuck Labs (Shattuck) a biotechnology company that develops bi-functional fusion proteins for the treatment of cancer and autoimmune disease. The company develops products using its proprietary agonist redirected checkpoint (ARC) platform and gamma delta T Cell engager (GADLEN) platform. Shattuck’s lead products include, SL-172154 (SIRPa-Fc-CD40L) developed for the treatment of ovarian cancer, cutaneous squamous-cell carcinoma (cSCC) and head and neck squamous cell carcinoma (HNSCC); and SL-279252 (PD1-Fc-OX40L) for advanced solid tumors and lymphoma. The company is also evaluating drugs targeting oncology, advanced solid tumors and autoimmune diseases. It operates a research and development office in Durham, North Carolina. Shattuck is headquartered in Austin, Texas, the United States.

For a complete picture of SL-279252’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.